On Monday, Iterum Therapeutics Plc (NASDAQ: ITRM) opened higher 18.32% from the last session, before settling in for the closing price of $2.02. Price fluctuations for ITRM have ranged from $0.81 to $2.34 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -39.15% over the last five years. Company’s average yearly earnings per share was noted 65.38% at the time writing. With a float of $26.60 million, this company’s outstanding shares have now reached $27.52 million.
The firm has a total of 14 workers. Let’s measure their productivity. In terms of profitability, gross margin is 82.63%, operating margin of -1009.81%, and the pretax margin is -1152.56%.
Iterum Therapeutics Plc (ITRM) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Iterum Therapeutics Plc is 3.33%, while institutional ownership is 6.16%. The most recent insider transaction that took place on Dec 22 ’23, was worth 35,000. In this transaction Director of this company bought 25,000 shares at a rate of $1.40, taking the stock ownership to the 113,754 shares. Before that another transaction happened on Dec 18 ’23, when Company’s Director bought 10,000 for $1.84, making the entire transaction worth $18,442. This insider now owns 88,754 shares in total.
Iterum Therapeutics Plc (ITRM) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.81 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.99) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.38% per share during the next fiscal year.
Iterum Therapeutics Plc (NASDAQ: ITRM) Trading Performance Indicators
Check out the current performance indicators for Iterum Therapeutics Plc (ITRM). In the past quarter, the stock posted a quick ratio of 0.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.00, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.73 in one year’s time.
Technical Analysis of Iterum Therapeutics Plc (ITRM)
Analysing the last 5-days average volume posted by the [Iterum Therapeutics Plc, ITRM], we can find that recorded value of 1.46 million was better than the volume posted last year of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 86.71%. Additionally, its Average True Range was 0.20.
During the past 100 days, Iterum Therapeutics Plc’s (ITRM) raw stochastic average was set at 98.14%, which indicates a significant increase from 97.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.56% in the past 14 days, which was lower than the 121.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.31, while its 200-day Moving Average is $1.35. Now, the first resistance to watch is $2.56. This is followed by the second major resistance level at $2.72. The third major resistance level sits at $3.03. If the price goes on to break the first support level at $2.09, it is likely to go to the next support level at $1.78. Should the price break the second support level, the third support level stands at $1.62.
Iterum Therapeutics Plc (NASDAQ: ITRM) Key Stats
There are currently 27,516K shares outstanding in the company with a market cap of 65.44 million. Presently, the company’s annual sales total 0 K according to its annual income of -38,370 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -6,090 K.
